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Deliriuma b s t r a c t
Inflammation influences chronic neurodegeneration but its precise roles are not yet clear. Systemic
inflammation caused by infection, trauma or co-morbidity can alter the brain’s inflammatory status, pro-
duce acute cognitive impairments, such as delirium, and drive new pathology and accelerated decline.
Consistent with this, elevated systemic TNF-a is associated with more rapid cognitive decline over
6 months in Alzheimer’s disease patients. In the current study we challenged normal animals and those
with existing progressive neurodegeneration (ME7 prion disease) with TNF-a (i.p.) to test the hypothesis
that this cytokine has differential effects on cognitive function, sickness behavior and features of
underlying pathology contingent on the animals’ baseline condition. TNF-a (50 lg/kg) had no impact
on performance of normal animals (normal brain homogenate; NBH) on working memory (T-maze)
but produced acute impairments in ME7 animals similarly challenged. Plasma TNF-a and CCL2 levels
were equivalent in NBH and ME7 TNF-challenged animals but hippocampal and hypothalamic transcrip-
tion of IL-1b, TNF-a and CCL2 and translation of IL-1b were higher in ME7 + TNF-a than NBH + TNF-a
animals. TNF-a produced an exaggerated sickness behavior response (hypothermia, weight loss, inactiv-
ity) in ME7 animals compared to that in NBH animals. However a single challenge with this dose was not
sufficient to produce de novo neuronal death, synaptic loss or tau hyperphosphorylation that was distin-
guishable from that arising from ME7 alone. The data indicate that acutely elevated TNF-a has robust
acute effects on brain function, selectively in the degenerating brain, but more sustained levels may be
required to significantly impact on underlying neurodegeneration.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
It has become clear that inflammation contributes to chronic
neurodegeneration but its precise roles are not yet clear and there
remains no effective treatment for slowing the progression of
chronic conditions such as Alzheimer’s and Parkinson’s disease.
There is substantial epidemiological evidence that inflammatory
co-morbidities are significant risk factors for dementia (Yaffe
et al., 2004; Dunn et al., 2005; Reitz et al., 2011) and taking non-
steroidal anti-inflammatory drugs protects against subsequent
development of AD (Etminan et al., 2003). Consistent with a role
of co-morbid inflammation, we and others have shown that
systemic inflammation can robustly alter brain inflammatory
status, inducing a switching of microglial phenotype from ‘primed’to activated or from M2 to M1, with the consequence of acutely
elevated brain levels of IL-1b (Cunningham et al., 2005; Godbout
et al., 2005; Pott-Godoy et al., 2008). The pro-inflammatory cyto-
kine IL-1b has been shown to contribute to impaired cognitive
function and decreased neuronal viability (Relton and Rothwell,
1992; Vereker et al., 2001; Balosso et al., 2008; Pott-Godoy et al.,
2008; Vezzani et al., 2011) in a number of model systems. In ani-
mal models of chronic neurodegeneration, such superimposed
inflammatory activation can produce de novo pathology and has
been shown to exacerbate the progression of neurodegenerative
disease (Sheng et al., 2003; Kitazawa et al., 2005; Lee et al.,
2008; Cunningham et al., 2009; Field et al., 2010; Krstic et al.,
2012). However the mechanisms by which systemic inflammation
exacerbate neurodegeneration remain unclear.
While many systemic inflammatory molecules may exacerbate
cognitive decline, the role of systemic TNF-a has been of particular
interest. It has been shown in a clinical population of AD patients
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more rapid cognitive decline over 6 months (approximately 2-
fold) and when those patients with SIE also had elevated plasma
TNF-a levels, this was associated with a 10-fold greater rate of cog-
nitive decline over the 6 month observation period (Holmes et al.,
2009). Analysis of the Neuropsychiatric inventory (NPI) from the
same cohort showed that elevated systemic TNF-a was associated
with a 2-fold increase in symptoms characteristic of sickness
behavior including apathy, anxiety, depression and agitation
(Holmes et al., 2011). Elevated baseline TNF-a has also been asso-
ciated with lower hippocampal volume (Sudheimer et al., 2014)
and with greater likelihood of mild cognitive impairment (MCI)
patient conversion to AD (Tarkowski et al., 2003) suggesting
increased systemic TNF-amay have roles in hippocampal neurode-
generation. Neuroscientific studies of TNF-a have revealed a
potentially complex biphasic role: administration of anti-TNF-a
antibodies i.c.v. decreased Ab, tau hyper-phosphorylation and
memory deficits in AD-related models (Medeiros et al., 2007; Shi
et al., 2011) but crossing of 3xTgAD mice with TNFR1/R2 double
knockout mice actually exacerbated amyloid and Tau pathology
and microglia from these mice had impaired phagocytic ability
(Montgomery et al., 2011).
We sought to specifically investigate whether exogenously
added systemic TNF-a has deleterious effects on cognitive
function, inflammation, sickness behavior and neurodegeneration
on a background of robust chronic neurodegeneration. In this study
we used the ME7 model of prion disease, which shows robust
synaptic loss, extracellular amyloidosis and a sequence of
behavioral and cognitive impairments (Betmouni et al., 1999;
Cunningham et al., 2003) and which we have previously shown
to show acute neuronal death and more rapid decline after
systemic challenge with LPS (Cunningham et al., 2005, 2009). We
assessed the cognitive-disrupting effects of acute systemic TNF-a
in ME7 and normal brain homogenate-injected controls (NBH)
using a T-maze working memory test. We then examined
hippocampal and hypothalamic mRNA, plasma proteins and
hippocampal IL-1b protein induced by systemic TNF-a. The
interaction of systemic TNF-a with existing pathology was also
measured in ME7 and NBH animals using standard measures of
sickness behavior: core body temperature, weight loss and open
field activity. Finally the occurrence of de novo neuronal pathology
after a single (i.p.) challenge with TNF-a was explored using quan-
tification of apoptotic cell death, synaptic loss and tau hyperphos-
phorylation post-TNF-a in ME7 and NBH animals.
2. Methods
2.1. Animals and stereotaxic surgery
Female C57BL/6 mice (Harlan, Bicester, United Kingdom) were
housed in cages of 5 at 21 C with a 12:12 light, dark cycle. Food
and water access was ad libitum. Mice were anaesthetized
intraperitoneally (i.p.) with Avertin (2,2,2-tribromoethanol 50%
w/v in tertiary amyl alcohol, diluted 1:40 in H2O; 20 ml/kg, i.p.;
Sigma) and positioned in a stereotaxic frame (Kopf instruments).
Holes were drilled at 2.0 mm (anteroposterior) and ±1.6 mm (lat-
eral, either side of the midline) from Bregma and 1 ll 10% w/v
ME7-infected C57BL/6 brain homogenate was injected into the
hippocampus using a Hamilton microsyringe (Reno, Nevada,
USA) to a depth of 1.7 mm. The needle was left in situ for
2 min before slow withdrawal. Control animals were administered
1 ll 10% w/v normal brain homogenate (NBH). Mice were placed in
an incubator at 25 C for recovery. When returned to their home
cage they were administered Sucrose (5% w/v) and Carprofen
(0.05% v/v; Rimadyl, Pfizer, Ireland) in their drinking water for
2 days post-surgery. Animals were monitored for recovery fromsurgery. All animal experimentation was performed under a
license granted by the Minister for Health and Children, Ireland,
with approval from the TCD Animal Research Ethics Committee
and in compliance with the Cruelty to Animals Act, 1876 and the
European Community Directive, 86/609/EEC. Every effort was
made to minimize stress to the animals.
Animals were intraperitoneally administered recombinant
mouse TNF-a (Peprotech, Rocky Hill, NJ, USA) at doses of 50 lg/
kg or 250 lg/kg prepared in sterile saline (Sigma, Poole, UK). Lower
doses were used for the T-maze experiments and higher doses for
the pathology experiment. Our previous studies using these 2 TNF
doses (Skelly et al., 2013) suggested that sickness at the earliest
times points assessed was not terribly different between these 2
doses. Therefore we performed our cognitive experiments with
the minimum dose that was practical (50 lg/kg i.p.) since more
robust sickness may suppress the mouse behavioral repertoire
too significantly to allow robust assessment of cognitive function
(due to motivational and motor confounders). However, it has been
our experience with LPS effects on cognition and de novo pathology
that more intense systemic inflammation was required to produce
damage (500 lg/kg LPS; (Cunningham et al., 2005)) versus that
required to produce measureable cognitive dysfunction (100 lg/
kg; (Murray et al., 2012)). This five-fold difference in potency
guided our choice of doses in the current experiments with TNF-
a. Control animals were injected using sterile saline (Sigma, Poole,
UK) 200 ll per 20 g body weight. In additional experiments ME7
animals were challenged with LPS (Salmonella equine abortus,
500 lg/kg, Sigma, Poole, UK) in the presence or absence of the
dominant negative TNF inhibitor XPRO1595 (a generous gift from
David Szymkowski, Xencor, Monrovia, CA) at 30 mg/kg, i.p. 1 h
before treatment with LPS. Appropriate action of XPRO1595 was
assessed by administration of XPRO1595 (30 mg/kg i.p.) 1 h before
TNF-a (50 mg/kg) to block TNF-induced hypothermia.
These TNF-a challenges were made at 16 weeks for T-maze
experiments since we have previously established that ME7 ani-
mals at 18 weeks can no longer perform the T-maze at baseline
(ie before acute inflammatory challenge). However our prior
demonstrations of de novo neuropathology induced by systemic
inflammation in ME7 animals has been exclusively at 18–
19 weeks, which is the period when neuronal cell soma loss is
determined to be occurring in this prion model (Cunningham
et al., 2003, 2005).
2.2. Working memory
Hippocampal-dependent working memory was assessed in
mice by observing alternation behavior in a novel water T-maze
task (Murray et al., 2012). The T-maze, constructed from black per-
spex, was of the following dimensions (cm); long axis 67, short axis
38, depth 20 and arm width 7. Single 4 cm diameter holes were at
the end of each choice arm, 2 cm from the floor and black exit
tubes were fitted into these holes. Solid or permissive exit tubes
could be fitted into these holes as appropriate, to facilitate/block
escape at any location. A ‘‘guillotine” door was inserted to prevent
access to one or other choice arm on the first run of each trial.
Water to a depth of 2 cm at a temperature of 20 C was poured into
the maze; at this height a mouse must paddle and thus is moti-
vated to leave the maze through an exit tube. Animals were taken
with their cage mates to a holding cage. Each mouse was individ-
ually placed in the start arm of the maze with 1 arm blocked, such
that they were forced to make a left or right turn. The arm
sequences were chosen in a pseudo-random manner, with equal
numbers of left and right turns in any one session; moreover, there
were no more than 2 consecutive runs to the same arm. On making
the turn the mouse could escape from the water by entering the
exit tube and walking to a transit tube, in which it was carried to
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30 s intra-trial interval, in which the guillotine door was removed
and exit tube switched to the opposite arm. The mouse was then
replaced in the start arm and could choose either arm. Since the
exit tube which it had escaped through was now blocked, the
mouse must alternate from its original turn to escape. On choosing
correctly the mouse escaped to the transit tube and was returned
to its home cage. On choosing incorrectly the mouse was allowed
to self-correct to the correct exit arm. Animals were typically
trained for >10 blocks of 10 trials (inter-trial interval of 20 min)
before other experimental manipulations are performed. Most ani-
mals reached baseline alternation of greater than 80%. No animals
were experimentally challenged unless they performed at 70% or
above for consecutive days. Furthermore, no animals that
performed lower than 80% in the last block of 5 trials or displayed
evidence of a side preference on the day prior to experimental
challenges were included. Thereafter, animals were challenged
with saline or TNF-a (50 lg/kg) and then tested in the T-maze
for 15 trials across 6 h (1–3 h, 3–5 h and 5–7 h) and again at one
day later to assess recovery.2.3. Sickness behavior
An ‘open field’ consisted of a plastic base (58 cm  33 cm)
surrounded by walls of 19 cm. The floor of the box is divided into
a grid of equal sized squares. Measurement was made of distance
travelled (grid squares crossed) and total number of rears (fre-
quency with which the mice stood on their hind legs in the maze).
Each animal’s baseline activity was measured prior to experimen-
tation. Animals were scored for 2 min in the Open Field.
A thermocouple rectal probe (Thermalert TH5, Physitemp;
Clifton, NJ, USA) was used to measure core body temperature.
The mice were habituated to measurement of rectal temperature
for 2 days prior to experimentation to minimize/standardise stress
effects. Baseline temperature was taken at the time of challenge,
followed by the timepoints indicated. Body weight was likewise
taken immediately before challenge and at a number of times up
to 18 h (the time point at which these animals were euthanised
and perfused for histopathology).2.4. Tissue preparation
Animals for mRNA and protein analysis were terminally anaes-
thetised with sodium pentobarbital at 2 or 4 h post-challenge
(Euthatal, Merial Animal Health, Essex, UK). The thoracic cavity
was opened and blood collected in heparinised tubes directly from
the right atrium of the heart. The animal was then rapidly transcar-
dially perfused with heparinised saline to wash out the blood.
Whole blood was spun at 1500xg for 15 min to remove cells and
the plasma was then aliquoted and stored at 20 C. Three tissue
punches were taken from the brain: the left hippocampus, right
hippocampus and the hypothalamus at the appropriate anterior-
posterior coordinates from Bregma. Tissue was snap-frozen in
liquid nitrogen and was stored at 80 C until use.
Animals for immunohistochemical examination were termi-
nally anaesthetised with sodium pentobarbital (Euthatal, Merial
Animal Health, Essex, UK) at 9 or 18 h post-challenge and transcar-
dially perfused with heparinised saline for approximately 3 min
followed by 10% neutral buffered formalin (Sigma, Poole, UK) for
approximately 15 min. Brains were post-fixed in formalin and then
embedded in paraffin wax. Coronal sections (10 lm) were cut on a
Leica RM2235 Rotary Microtome (Leica Microsystems, Wetzlar,
Germany) at the level of the hippocampus and floated onto electro-
statically charged slides (Menzel-Glaser, Braunschweig, Germany)
and dried at 37 C overnight.2.5. Plasma ELISA assays
Plasma samples were diluted appropriately and then analysed
for TNF-a and CCL2. Mouse TNF-a and CCL2 were quantified by
sandwich-type ELISA, using R&D systems duo set kits (R&D sys-
tems, Minneapolis, MN, USA). A standard protocol was followed.
The capture anti-TNF-a and CCL2 antibodies were diluted 1/180
(approximately 1 lg/ml) in PBS, and used to coat a 96-well max-
isorb microplate overnight (Nunc, Fisher Scientific, Leicestershire)
with 100 ll per well. Plates were then washed with PBS + 0.05%
Tween and blocked with PBS + 1% BSA before addition of 100 ll
samples and standards for 2 h at room temperature. Detection
antibodies were used at a dilution of 1/180 and incubated on the
plates for 1.5 h. Streptavidin poly-horseradish peroxidase (HRP:
Sanquin, Amsterdam, Netherlands) was diluted in 1:10,000 and
incubated in the dark at room temperature for 20 min. Samples,
standards, detection antibodies and streptavidin poly-horseradish
peroxidase were diluted in high performance ELISA buffer
(Sanquin; Amsterdam, Netherlands). TMB and H2O2 were used as
substrate and the reaction was stopped with 1 M H2SO4 before
optical density was read at 450 nm with correction at 570 nm.
Standard curves were constructed and samples were quantified
only if the absorbance fell on the linear portion of the standard
curve. IL-1b protein in the hippocampus was quantified using a
Quantikine mouse IL-1b kit (R&D systems, Minneapolis, MN,
USA) according to manufacturer’s instructions.
2.6. RNA extraction and quantitative PCR
Total RNA was isolated using the RNeasy Plus Mini method
(Qiagen, Limburg, Netherlands) as per the manufacturer’s instruc-
tions. To ensure complete DNA elimination from the column-
bound RNA, an on-column DNase step was performed. The RNA
yield and quality of each sample was quantified based on Optical
Density (OD) using the NanoDrop’ND-1000 UV–vis spectropho-
tometer (Thermo Fisher Scientific, Dublin, Ireland). cDNA synthesis
was carried out using a High Capacity cDNA Reverse Transcriptase
Kit (Applied Biosystems, Warrington, UK). cDNA was stored at
20 C until use in RT-PCR. All primer and probe sets were
designed using Applied Biosystems Primer Express software and
amplified a single sequence of the correct amplicon size, as verified
by SDS-PAGE. Where no probe sequence is shown, the DNA binding
dye SYBR green was used in its place. Primer pair/probe sequences
are shown in Table 1. Samples for RT-PCR were run in duplicate
and contained 12.5 ll Faststart universal probe master mix (Roche,
Lewes, UK), 0.5 ll of each of the forward primer (10 lM), reverse
primer (10 lM) and probe (10 lM), and 10 ll RNase-free water.
All PCR was carried out in a StepOne Real-Time PCR system
(Applied Biosystems, Warrington, UK) under the cycling condi-
tions: 95 C for 10 min followed by 95 C for 10 s and 60 C for
30 s for 40 cycles. Quantification was achieved by exploiting the
relative quantitation method, using cDNA from LPS-injected mouse
brain as a standard expressing all genes of interest and fourfold
serial dilutions of this cDNA to construct a linear standard curve
relating cycle threshold (CT) values to relative concentrations. This
method has been described in detail elsewhere (Cunningham et al.,
2005). Gene expression data were normalized to the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
2.7. Immunohistochemistry
Sections were labelled with IBA-1, 1/2000, ab5076 (Abcam,
Cambridge, UK), SY38, 1/2000 (Millipore, Cork, Ireland), AT8,
1/200, MN1020 (Thermo Scientific, MA, USA), Caspase 3, 1/50,
ab3623 (Millipore, Cork, Ireland); SY38 sections were treated with
0.2 M boric acid, pH 9 at 65 C for 30 min then cooled to room
Table 1
Primer pair/probe sequences. Where no probe sequence is shown, SYBR green dye was used instead.
Gene Access. num. Length Sequence
COX-1 NM_008969 70 bp Forward: 50-CCAGAACCAGGGTGTCTGTGT-30
Reverse: 50-GTAGCCCTGCGAGTACAATC-30
Probe: 50-CGCTTTGGCCTCGACAACTACCAGTG-30
COX-2 NM_011198.4 128 bp Forward: 50-TGGGTGTGAAGGGAAATAAGGA-30
Reverse: 50-GAAGTGCTGGGCAAAGAATG-30
CCL2 NM_011333 81 bp Forward: 50-GTTGGCTCAGCCAGATGCA-30
Reverse: 50-AGCCTACTCATTGGGATCATCTTG-30
Probe: 50-TTAACGCCCCACTCACCTGCTGCTACT-30
IL-1b M15131 69 bp Forward: 50-GCACACCCACCCTGCA-30
Reverse: 50-ACCGCTTTTCCATCTTCTTCTT-30
Probe: 50-TGGAGAGTCTGGATCCCAAGCAATACCC-30
RANK NM_009399.3 63 bp Forward: 50-TCGTCCACAGACAAATGCAAA-30
Reverse: 50-GTGTGCTTCTAGTTTCCAAGGA-30
Probe: 50-CTTGGACCAACTGCA-30
RANK Ligand NM_011613.3 112 bp Forward: 50-GGGGGCCGTGCAGAAGGAAC-30
Reverse: 50-CTCAGGCTTGCCTCGCTGGG-30
TNF-a M11731 149 bp Forward: 50-CTCCAGGCGGTGCCTATG-30
Reverse: 50-GGGCCATAGAACTGATGAGAGG-30
Probe: 50-TCAGCCTCTTCTCATTCCTGCTTGTGG-30
GAPDH NM_008084.2 65 bp Forward: 50-GACGGCCGCATCTTCTTGT-30
Reverse: 50-CACACCGACCTTCACCATTTT-30
Probe: 50-CAGTGCCAGCCTCGTCCCGTAGA-30
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1% H2O2/methanol (20 min). Sections were then pre-treated with
citrate buffer (pH 6) for 2  5 min in the microwave (except
SY38). IBA-1 sections were then pre-treated with 0.04% pepsin in
0.1 M HCl for 20 min prior to blocking. Slides were blocked with
the appropriate serum. Primary antibodies were incubated over-
night at 4 C. Thereafter the ABC method was used as previously
described (Cunningham et al., 2005) with peroxidase as enzyme,
3,30-Diaminobenzidine as chromogen and H2O2 as substrate. Slides
were counterstained using Haemotoxylin (VWR International Ltd,
Dublin, Ireland). The DeadEnd Fluorometric TUNEL system
(G3250, Promega) was used in conjunction with a biotinylated
anti-Fluorescein secondary to visualise apoptotic cells in accor-
dance with manufacturer’s instructions.2.8. Immunohistochemical quantification
TUNEL-positive and Caspase-3-positive cells were counted by
two experimentors, blinded to experimental treatment. Tau was
quantified in the CA3 region by determining the area fraction
labelled by the AT8 antibody. The density of synaptophysin
staining was determined by monochrome pixel density analysis
of digitally captured images using Leica QWIN image analysis soft-
ware (Leica, Milton Keynes, UK) as described in (Cunningham et al.,
2003). The transmittance of the stratum radiatum was expressed
as a ratio to the transmittance in the stratum lacunosum (a layer
relatively low in staining, to achieve a contrast) or as a ratio to
the mossy fibre layer (a layer maintaining reasonably dark staining
throughout the progression of disease) as follows:
Ratio ¼ ðTdentate gyrus  TradiatumÞ=ðTdentate gyrus  TlacunosumÞ
IBA-1 quantification: The number of Iba-1 positive cells was
determined, in 10 lm sections, in the dorsal part of the hippocam-
pus (between dentate gyrus granule and CA1 pyramidal layers) in
high-quality microphotographs taken under 20X objective. At least
four counting frames per animal were analysed (equal left and
right hemisphere) with Image J software (NIH, Bethesda, MD,
USA). Files were converted to 8 bit binary images and the intensity
threshold set at 150. The number of cells per field (0.280 mm2) was
automatically determined by counting all the objects between 200
and 6000 pixels2.2.9. Statistics
Behavioral data were analysed using 3-way ANOVA (with
disease and treatment as between subjects factors and time as a
repeated measures, within subjects, factor) followed by Bonferroni
post-hoc pair-wise comparisons where appropriate. Molecular data
were analysed using 2-way ANOVA followed by Bonferroni post-
hoc tests. Histological counts were analysed using one-way ANOVA
followed by Dunnett’s multiple comparison.3. Results
3.1. Cognitive deficits following systemic TNF-a
The effect of TNF-a (50 lg/kg) on working memory was exam-
ined using the alternation T-maze. All animals were confirmed to
have acceptable baseline performanceP70% for three consecutive
days pre-challenge. On the days of saline or TNF-a treatments, ani-
mals underwent 3 blocks of 5 trials (between 1 and 7 h post-
challenge) and 2 further blocks of 5 trials at 24-h post-challenge
to confirm recovery. Systemically administered TNF-a induced a
transient deficit in working memory in the T-maze task in ME7
animals, while there were no deficits in NBH animals similarly
challenged (Fig. 1). Using 3-way repeated measures ANOVA there
was an interaction between disease, treatment and time following
systemic TNF-a challenge (P < 0.01, F6,328 = 3.09). An a priori pre-
diction from previous studies in the laboratory suggested that
the effect of TNF-a on working memory would be a transient one
(Fig. 1) and at the one hour (P < 0.01) and three hour (P < 0.05)
timepoints following systemic TNF-a, ME7 + TNF-a animals were
significantly different from all other treatment groups. Therefore,
prior neurodegeneration in the ME7 model is a risk factor for acute
cognitive deficits following acute systemic elevation of TNF-a.3.2. Systemic TNF-a induces heightened CNS inflammatory response
Transcripts for selected inflammatory cytokines were examined
in the hippocampus and hypothalamus following systemic TNF-a
administration. IL-1b, TNF-a and the chemokine CCL2 all showed
acute elevation after systemic TNF-a that was greater in ME7
animals than in NBH.
Fig. 1. Impact of systemic TNF-a on working memory in NBH and ME7 animals.
Percentage T-maze alternation post-systemic TNF-a (50 lg/kg) or saline adminis-
tration in ME7 or NBH animals, 16 weeks post-inoculation. Data were analysed
using a two-way ANOVA followed by a Bonferroni multiple comparison test
comparing individual time-points. Three-way ANOVA was used to test overall
significance. Statistically significant differences are denoted by ⁄(P < 0.05),
⁄⁄(P < 0.01), ⁄⁄⁄(P < 0.001). All data are represented as the mean ± SEM, n = 9–15
for all groups.
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[F(1,18) = 24.66, P < 0.001]. Post-hoc Bonferroni comparisons
revealed a significant difference between NBH + TNF-a and ME7
+ TNF-a at 2 h (P < 0.01) and between NBH + saline and ME7 +
saline (P < 0.05) (Fig. 2a). Disease [F(1,21) = 72.99, P < 0.001], and
TNF-a administration [F(2,21) = 10.97, P < 0.001] both significantly
increased hippocampal TNF-a expression. Post-hoc comparisons
showed that disease was associated with significantly (p < 0.01)
higher hippocampal TNF-a mRNA expression across all treatment
groups (P < 0.001) (Fig. 2b). CCL2 mRNA expression in the hip-
pocampus following peripheral TNF-a administration revealed a
significant effect of disease [F(1,18) = 49.15, P < 0.001], and of
TNF-a [F(2,18) = 9.03, P < 0.01]. Post-hoc Bonferroni comparisonsFig. 2. Central and systemic inflammatory markers post-systemic TNF-a. Hippocampal (a
at 2 and 4 h post TNF-a (50 lg/kg) i.p in ME7 or NBH animals, 16 weeks post-inoculation
Statistically significant differences between NBH and ME7 groups are denoted by ⁄(P < 0.
are represented as the mean ± SEM, n = 3–5 for all groups.revealed significant differences between NBH + TNF-a at 2 h and
ME7 TNF-a at 2 h (P < 0.001) but also between NBH + saline and
ME7 + saline (P < 0.001) (Fig. 2c).
The same inflammatory genes were examined in the hypothala-
mus following TNF-a administration. IL-1b mRNA showed a
significant effect of disease [F(1,20) = 32.53, P < 0.0001], and of TNF-
a treatment [F(2,20) = 20.03, P < 0.0001], but no significant dis-
ease  treatment interaction. Post-hoc Bonferroni comparison
revealed a significant increase in IL-1b mRNA expression in the
hypothalamus in all ME7 groups compared to all NBH groups
(Fig. 2d): saline (P < 0.05), TNFa-2 h (P < 0.01) and TNF-a 4 h
(P < 0.05). TNF-a mRNA expression in the hypothalamus revealed
a significant effect of disease [F(1,20) = 28.47, P < 0.0001] and of
TNF-a treatment [F(2,20) = 19.5 P < 0.0001] but there was no
disease  treatment interaction (Fig. 2e). Nonetheless, post-hoc
Bonferroni comparison revealed a significant increase in TNF-a
mRNA expression in ME7 treated with TNF-a at 2 h (P < 0.05) and
4 h (P < 0.01) in comparison to the same treatments inNBH animals.
CCL2mRNA in the hypothalamus revealed a significant effect of dis-
ease [F(1,20) = 10.53, P < 0.01] and TNF-a treatment [F(2,20) = 58.34,
P < 0001]. In the case of CCL2, post-hoc Bonferroni comparison
revealed no significant difference between NBH+ TNF-a and ME7
+ TNF-a groups in the hypothalamus at 2 h post-challenge (Fig. 2f).
Systemic levels of TNF-a and CCL2 proteins were examined in
the plasma using ELISA (Fig. 2g,h). TNF-a treatment predictably
significantly increased serum TNF-a protein levels [F(2,24) =
45.67777, P < 0.0001]. CCL2 also showed a significant increase in
plasma following TNF-a treatment [F(2,21) = 11.71, P < 0.001] but
levels of both of these cytokines were equivalent in TNF-a-
challenged ME7 and NBH animals.
Hippocampal expression of IL-1b protein was examined using
ELISA following systemic TNF-a administration (Fig. 2i). IL-1b
protein in the hippocampus was modestly increased by disease
[F(1,19) = 19.8, P < 0.001] and by TNF-a treatment [F(2,19) = 3.53,
P < 0.05]. However, there was also a significant disease  treatment-c) and hypothalamic (d-f) transcripts, and plasma (g-h) and hippocampal (i) protein
. Data were analysed using a two-way ANOVA followed by Bonferroni post-hoc test.
05), ⁄⁄(P < 0.01), ⁄⁄⁄(P < 0.001). # denotes a disease  treatment interaction. All data
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parison revealed a significant increase in hippocampal IL-1b protein
inME7animals compared toNBHanimals at both 2 (P < 0.001) and4
(P < 0.05) hours post-TNF-a.
To further explore the brain inflammatory milieu, the hypotha-
lamic mRNA expression of other genes implicated in sickness
behavior and thermoregulation were assessed (Fig. 3). COX-2
mRNA expression was significantly increased by TNF-a treatment
at 2 h, with this increase declining by 4 h (Significant effect of
treatment [F(2,21) = 3.624, P < 0.05]; Fig. 3a). TNF-a did not have dif-
ferent effects in NBH and ME7 animals.
COX-1 was not significantly altered by TNF-a treatment but
was significantly increased in diseased versus normal animals.
Two way ANOVA revealed a significant effect of disease
[F(1,21) = 60.76, P < 0.0001] and post-hoc Bonferroni comparisons
showed a significant difference between NBH + saline and ME7
+ saline (P < 0.05) and between NBH + TNF-a and ME7 + TNF-a at
2 h (P < 0.001) and at 4 h (P < 0.01) (Fig. 3b).
Receptor activator of nuclear factor jB (RANK) expression was
slightly increased by TNF-a treatment and slightly increased by
disease per se. Both disease [F(1,21) = 11.10, P < 0.005] and treat-
ment [F(2,21) = 4.04, P < 0.05] showed significant effects, albeit with
a small effect size.
Regarding RANK ligand (RANKL), this was robustly induced by
TNF-a, particularly in ME7 animals. Two way ANOVA showed a
significant effect of disease [F(1,21) = 5.65, P < 0.05] and treatment
[F(2,21) = 9.072, P < 0.005]. Although the interaction was not quite
significant [F(2,21) = 2.75] Bonferroni post-hoc test revealed a sig-
nificant increase in ME7 + TNF-a at 2 h when compared with
NBH + TNF-a at 2 h (P < 0.01) (Fig. 3d).3.3. TNF-a induces an exaggerated sickness response in ME7 animals
The data on CNS cytokines and RANKL predicted differential
effects of systemic TNF-a (250 lg/kg) on sickness parameters inFig. 3. Expression of genes implicated in hypothalamic thermoregulatory activity. Change
jB (RANK) (c) and receptor activator of nuclear factor jB ligand (RANK Ligand) (d) after
(50 lg/kg) in NBH and ME7 animals. Data were analysed using two way ANOVA follo
⁄⁄(P < 0.01), ⁄⁄⁄(P < 0.001). All data are represented as the mean ± SEM, n = 4–5 for all grNBH and ME7 animals. Therefore core body temperature, body
weight, locomotor activity and rears in the open field were exam-
ined at the indicated times post-challenge. TNF-a induced acute
hypothermia peaking at 2 h and returning gradually to baseline
at 18 h (Fig. 4a). The reduction in core body temperature was
significantly more severe in ME7 animals. There was a main effect
of TNF-a (P < 0.001, F(1,174) = 19.91) and an interaction between
disease, treatment and time (P < 0.001, F(4,174) = 15.94). TNF-a
caused modest weight loss, presumably by inducing acute
hypophagia following treatment (P < 0.0001, F(1,104) = 34.36) and
this was also somewhat greater in ME7 + TNF-a animals, when
measured at 18 h (Fig. 4b). There was an interaction between treat-
ment and time (P < 0.0001, F(2,104) = 17.63).
TNF-a challenge appeared to reduce levels of activity in the
open field (Fig. 4c) but this was only evident in the ME7 + TNF-a
group (Fig. 4c), showing a particularly robust decrease in activity
at 3 h (P < 0.001). There was a main effect of TNF-a (P < 0.01,
F(1,139) = 8.58) and an interaction between disease, treatment and
time (P < 0.01, F(3,139) = 4.67). There was no main effect of treat-
ment on rears however, there was a robust interaction between
disease, treatment and time (P < 0.001, F(3,139) = 11.06). The ME7
+ TNF-a group once again showed a prolonged decrease in rearing
activity following systemic TNF-a treatment (Fig. 4d) while no
such decrease was observed with NBH + TNF-a animals. Thus
TNF-a has significantly greater activity suppression in animals
with prior degeneration than in normal animals.3.4. A single i.p. challenge with TNF-a does not exacerbate ME7
pathology
The effect of a single systemic challenge with TNF-a (250 lg/kg)
on ME7 pathology was examined using markers for microglial
activation and neuronal and synaptic pathology (synaptophysin,
Tau, IBA-1, activated caspase 3 and TUNEL). Synaptophysin was
significantly decreased in the hippocampal layers by ongoings in the mRNA expression of COX-2 (a) COX-1 (b) receptor activator of nuclear factor
i.p. challenge with non-pyrogenic saline or 2 or 4 h after systemic TNF-a treatment
wed by Bonferroni post-hoc test. Statistical significance is denoted by ⁄(P < 0.05),
oups.
Fig. 4. Impact of systemic TNF-a on sickness behavior in NBH and ME7 animals. Sickness behavior was examined following TNF-a (250 lg/kg) i.p. administration in ME7
prion diseased mice 18 weeks post-inoculation. Temperature change and body weight are presented as change from baseline. Rears and open field are graphed as percentage
of baseline. Data were analysed using a three-way ANOVA followed by Bonferroni multiple comparison test comparing each treatment group to its relevant control group.
Statistical significance is denoted by ⁄(P < 0.05), ⁄⁄(P < 0.01), ⁄⁄⁄(P < 0.001). All data are represented as the mean ± SEM, n = 6–15 for all groups.
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However, this was not further decreased 9 or 18 h post-systemic
TNF-a (Fig. 5a–d, e). There was significant deposition of
Hyperphosphorylated Tau throughout coronal sections from ME7
animals with significant concentration in the CA3 region (Fig. 5f–i).
This was not altered by administration of systemic TNF-a (Fig. 5j).
Microgliosis was evident with the ongoing ME7 pathology and the
major difference was between NBH animals and all ME7 groups
(Fig. 5k–n, m). However there was an apparent moderate increase
in IBA-1 positive cells at 9 h post-TNF, which was not apparent at
18 h post-TNF. After a significant one-way ANOVA, ME7 + TNF at
9 h was significantly different to both ME7 + saline (p < 0.05) and
ME7 + TNF 18 h (p < 0.001).
Both caspase 3 and TUNEL were used to determine whether sys-
temic TNF-a could increase ongoing apoptosis in the ME7 model
(examples in Fig. 5q). In all regions counted in ME7 animals there
was a significant level of ongoing apoptosis, as shown by increased
numbers of activated caspase 3-positive cells in the ME7 groups
(Fig. 5p, q). However TNF-a did not induce further statistically sig-
nificant increases in the numbers of these cells.
Terminal deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) was also used to visualise apoptosis since it labels frag-
mentation of nuclear DNA. TUNEL-positive cells appeared through-
out coronal sections of ME7 brains, appearing as dense labelling
within a condensed nucleus. In the hippocampus the ME7 + Saline
group significantly greater levels of apoptosis were apparent com-
pared to the NBH animals (P < 0.05; Fig. 5r) but the number of
TUNEL-positive apoptotic cells was not significantly increased by
administration of systemic TNF-a, suggesting that acutely elevatedTNF-a does not, of itself, significantly increase hippocampal cell
death even in the vulnerable brain. We had previously shown that
systemic LPS (500 lg/kg) acutely increases the number of TUNEL-
positive cells in the hippocampus (Cunningham et al., 2005) and
we thus interrogated whether blocking systemic TNF-a was suffi-
cient to protect against this acute cell death. TUNEL-positive cells
were quantified in the hippocampus of ME7 animals 18 weeks
post-inoculation; 18 h post i.p. challenge with saline or LPS
(500 lg/kg), having been pretreated with either PBS or the domi-
nant negative TNF inhibitor XPRO1595 (30 mg/kg). As previously
reported, systemic LPS induced a greater level of apoptosis in the
hippocampus (P < 0.0001, F(1,19) = 48.23) of ME7 animals (Fig. 5s)
but this was not mitigated by pre-treatment with XPRO1595. As
a positive control to demonstrate appropriate blockade of TNF-a
action by XPRO1595, mild TNF-a-induced hypothermia was
abrogated by XPRO1595 treatment (30 mg/kg) 60 min prior to
TNF-a (50 lg/kg; Fig. 5t).4. Discussion
In the current studywe have demonstrated that acutely elevated
systemic TNF-a is sufficient to induce acute cognitive dysfunction
and exaggerated sickness behavior and this occurs selectively in
animals with existing progressive neurodegeneration. Such a
heightened response to equivalent systemic inflammation could
be brought about by exaggerated CNS production of relevant pro-
inflammatory mediators, for which we present some evidence.
Although systemic TNF-a did further elevate the hippocampal and
Fig. 5. Immunohistochemical analysis of systemic TNF-a effects on prior pathology. Pathological examination was performed 18 h post-TNF-a (250 lg/kg) i.p in ME7 prion diseased mice 18 weeks post-inoculation. Labelling and
quantification was performed for Synaptophysin  5 (a–d, e), hyperphosphorylated Tau  40 (f–i, j), the microglial marker IBA-1  40 (k-n, o), and apoptosis markers Caspase 3  100 (p, q) and TUNEL x 100 (q, r). Data were
analysed using a one-way ANOVA followed by a Dunnett’s multiple comparison test. Statistical significance is denoted by ⁄(P < 0.05), ⁄⁄⁄(P < 0.001). All data are represented as the mean ± SEM, n = 3–5 for all groups. Additional
hippocampal analysis was performed in ME7 animals 18 weeks post-inoculation; 18 h post i.p. saline or LPS (500 lg/kg). Animals were pretreated with either PBS or XPRO1595 (30 mg/kg). TUNEL positive cells were quantified in
hippocampus (s) and data were analysed using two-way ANOVA followed by a Bonferroni multiple comparison test. Appropriate action of XPRO1595 (30 mg/kg) was verified by inhibition of TNF-a-induced (50 lg/kg) hypothermia
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single such challenge was not sufficient to induce measureable de
novo neuropathological changes.4.1. Acute cognitive dysfunction
The potential impacts of systemic inflammation on cognitive
function have been widely discussed in the literature. The evidence
that these effects are robust in normal healthy humans remains rel-
atively limited despite multiple rodent studies suggesting such def-
icits (Cunninghamand Sanderson, 2008; Yirmiya andGoshen, 2011;
Czerniawski and Guzowski, 2014). Though some effects have been
observed in humans these have been relatively mild or inconsistent
(Reichenberget al., 2001;Grigoleit et al., 2010) or notedon tasks that
are relatively difficult (Harrison et al., 2014). The evidence that sys-
temic inflammation has more robust effects on the frail or degener-
ating brain is accumulating in rodent studies (Barrientos et al., 2006;
Buchanan et al., 2008; Field et al., 2012;Murray et al., 2012) and this
is consistent with inflammatory triggering of human disorders such
as delirium, which is a profound and acute cognitive impairment
that frequently occurs during acute medical illness or after inflam-
matory traumas such as orthopedic fracture and surgery
(Cunningham and Maclullich, 2013; Inouye et al., 2014). Existing
cognitive impairment and neurodegenerative pathology are the
key risk factors for delirium incidence and it has been shown that
the risk of delirium is proportional to the extent of underlying
pathology/baseline cognitive impairment (Davis et al., 2015). It is
significant that in this model of acute systemic inflammation TNF-
a alone is sufficient to induce acute dysfunction in a cognitive task
reliant on attentional andworkingmemory function, two key cogni-
tive domains impaired in delirium. Associations between delirium
and TNF-a in biomarker studies have sometimes (Adamis et al.,
2011; Kazmierski et al., 2014), but not always (van den Boogaard
et al., 2011; Ritter et al., 2014), been detected. The current data are
certainly supportive of deleterious effects of systemic inflammation
on short-term cognitive processes. When patients show post-
surgical cognitive dysfunction but do not meet criteria for delirium
theymaybedescribedas experiencingpost-operative cognitivedys-
function (POCD). Although the termsdelirium, sub-syndromal delir-
ium and POCD are not always associated together, these probably
represent a severity continuumof cognitive impairments after acute
inflammatory/surgical trauma. A number of groups are now investi-
gating cognitive consequences of tibial fracture in rodents as a
model system for POCD. Memory consolidation deficits have most
often been studied using contextual fear conditioning and it has
been shown that tibial fracture-induced deficits in CFC could be
blocked via systemic blockade of TNF-a (Terrando et al., 2010). This
indicates that peripheral TNF-a may be a key acute injury-
associated cytokine that triggers cognitive changes during such epi-
sodes. Those studies showed acute TNF-a-dependent memory con-
solidation deficits even in young healthy animals upon tibial
fracture. The current study indicates that TNF-a alone is not suffi-
cient to impair workingmemorywhen administered to normal ani-
mals but can impair these cognitive domains when applied to
animals with existing neurodegenerative changes in the hippocam-
pus, thalamus and basal forebrain (Cunningham et al., 2003; Davis
et al., 2015). It is of interest that the studies of Terrando and col-
leagues showed that systemic TNF-a-induced memory consolida-
tion deficits were mediated via hippocampal expression of IL-1b,
the production of whichwas heightened in those animals with neu-
rodegeneration in the current study. Elevated CSF levels of IL-1b
have recently been shown to be associated with delirium in hip-
fracture patients (Cape et al., 2014). The causative role of TNF-a in
acute delirium and POCD, and potential involvement of brain IL-1b
require investigation in humans.4.2. Sickness Behavior and inflammatory mediator synthesis
TNF-a produced very marked hypothermia, weight loss and
suppression of activity in animals with existing neurodegenerative
disease, with respect to normal healthy animals similarly chal-
lenged. This cytokine, injected alone, has been reported to produce
mild but measureable sickness behavior in healthy normal animals
by ourselves and others (Bluthe et al., 1994; Swiergiel et al., 1997;
Skelly et al., 2013; Biesmans et al., 2015) and sickness induced by
other inflammatory stimuli such as bile-duct ligation (D’Mello
et al., 2009) and CD40 ligation (Cathomas et al., 2015) are reported
to be TNF-mediated. The sickness observed in normal animals in
the current study was not particularly robust, with mild effects
on core-body temperature and body weight and no clear decrease
in open field activity or rears. The analysis of the inflammatory
milieu (Figs. 2 and 3) demonstrate elevation of multiple inflamma-
tory markers, even at the lower doses used in these studies, and
these are consistent with other studies of similar doses
(Biesmans et al., 2015). It is possible that mild TNF-induced sup-
pression of activity is masked by habituation to the open-field
observed in saline-treated controls. Whatever the reasons for this
relatively limited response in normal animals, the ME7 + TNF-a
animals show marked hypothermia and robust hypoactivity by
measures of distance and rears, despite similar levels of circulating
cytokines, indicating exaggerated brain responses to equivalent
systemic inflammation. We have already described exaggerated
sickness responses of ME7 animals to LPS (Combrinck et al.,
2002) and this inflammatory hypersensitivity has been observed
also in aged animals (Godbout et al., 2005). Sickness behavior is
not routinely measured in humans but it is of interest that elevated
systemic TNF-a was associated with a 2-fold increase in neuropsy-
chiatric features in AD patients, including apathy, anxiety, depres-
sion and agitation, which are also characteristic of sickness
behavior (Holmes et al., 2011). Human volunteer studies with
bacterial endotoxin show an association between plasma TNF-a
and acute changes in anxiety (Lasselin et al., 2016). Our current
data, when assessed alongside these human association studies,
indicate that elevated TNF-a is likely to be causative in altering
aspects of human cognitive and affective behavior.
It is important to point out that the levels of circulating TNF-a at
the current doses (Skelly et al., 2013) are likely to be rather high
compared to those observed in humans during acute illness, but
are certainly comparable to those induced by experimental endo-
toxemia in humans (van den Boogaard et al., 2010). Moreover, at
50 lg/kg, TNF-a levels compare with those induced by low dose
LPS (100 lg/kg i.p.) and, at 250 lg/kg, levels compare with those
induced in mouse LPS (Pavlov et al., 2009) and cecal ligation and
puncture (Osuchowski et al., 2006) models of sepsis. Balancing this,
it is important to point out that these levels are rapidly cleared and
sickness in our TNF-treated animals is clearly rather limited in NBH
animals.
The hypothalamus is at the heart of many sickness-associated
changes with specific and well-characterised roles in fever and
anorexic responses (Dantzer et al., 2008; Saper et al., 2012). ME7
animals produce heightened levels of transcripts for hypothalamic
pro-inflammatory mediators, including TNF-a, upon exposure to
systemic TNF-a, compared to normal animals similarly challenged.
Although these hypothalamic responses are not elevated in a truly
exaggerated fashion, the heightened increase may be sufficient to
explain the more robust hypothermia and weight loss observed
in ME7 + TNF-a animals. However, we cannot rule out the possibil-
ity that neurons (in the hippocampus and/or hypothalamus) are
hyper-responsive to TNF-a or mediators induced by TNF-a.
Indeed it is likely that at least some of the effects of systemic
TNF-a are mediated by secondary inflammatory mediators. With
respect to hypothermic effects, TNF-a is generally described as a
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in mice independent of IL-1 (Mannel et al., 1987). However, pros-
taglandins, synthesised by cyclo-oxygenases 1 and 2 are the major
mediators of temperature and anorexic responses to LPS (Saper
et al., 2012) and systemic TNF-a also induces COX-2 transcription
and expression of COX-2 protein at the brain endothelium (Skelly
et al., 2013). Our current data show TNF-induced COX-2 expression
but this was not different in normal (NBH) and ME7 animals, indi-
cating that exaggerated sickness responses are not underpinned by
exaggerated COX-2 expression. It is conceivable that the disease-
associated increase in COX-1 (Fig. 3), which is consistent with
previous results in ME7 animals (Griffin et al., 2013), may make
some additional contribution to changes such as hypothermia
and hypoactivity, which have been shown to be robustly influ-
enced by prostaglandins (Teeling et al., 2010; Saper et al., 2012).
A very significantly elevated expression of RANKL in TNF-
treated ME7 animals may also contribute to the exaggerated
hypothermia observed. RANK and RANK ligand belong to the TNF
superfamily and they are critical for thermoregulation in the cen-
tral nervous system (see Hanada et al., 2010 for review). TNF-a is
a key regulator of the expression level of RANK and RANK ligand
(Hanada et al., 2010), inducing an increase in the expression of
both molecules. Our results showed effects of disease and treat-
ment in RANK and RANK ligand mRNA expression, increasing their
levels in ME7 and TNF-a-treated animals; theoretically supporting
the idea of this axis as a key thermoregulator in the current
paradigm. However, intracerebroventricular injection of RANKL is
reported to produce an acute febrile response via COX-2 activity
and PGE2-EP3 activation in the preoptic area of the hypothalamus
(Hanada et al., 2009). Therefore whether its increased expression
could contribute to the hypothermia observed here, without obvi-
ous differential effects on COX-2 requires further investigation.
It is also important to acknowledge that the mice used in this
studywere all female. This has beendone largely to avoid previously
observed fighting in males, but it is possible that the oestrus cycle
could have some influence on some of the sickness parametersmea-
sured here. Indeed it has been observed that RANKL contributes to
basal thermoregulation specifically in females (Hanada et al., 2009).
Although TNF-a (initially named cachectin) has significant
effects on muscle cachexia, it is more likely that short-term body
weight changes are mediated via decreased motivation to consume
foodwhich, in LPS and IL-1-induced sickness behavior, is also largely
mediated by prostaglandins. Similarly, although the neuroanatomy
and molecular mechanisms of sickness-induced hypoactivity
remain poorly understood both indomethacin (Teeling et al., 2007)
and the COX-1 inhibitor sc-560 (Griffin et al., 2013) reduced mea-
sures of LPS-induced sickness behavior and cognitive deficits with-
out effect on systemic or central TNF-a. Those data suggest that
prostaglandins would likely to act downstream of TNF-a but it will
be necessary to test whether any or all of the current TNF-induced
effects are mediated by prostaglandins.
4.3. Impact on underlying neurodegenerative pathology
Systemically applied LPS exacerbates existing pathology and
accelerates functional decline in multiple models of neurodegener-
ation including prion disease, amyotrophic lateral sclerosis, Parkin-
son’s disease and Alzheimer’s disease (Sheng et al., 2003; Nguyen
et al., 2004; Pott-Godoy et al., 2008; Cunningham et al., 2009) and
there is evidence that acute illness, infection and inflammatory co-
morbidity contribute to cognitive decline in Alzheimer’s disease
(Yaffe et al., 2004; Holmes et al., 2009; Pandharipande et al., 2013;
Widmann and Heneka, 2014). While many systemic inflammatory
molecules may exacerbate cognitive decline, the role of systemic
TNF-a is currently of particular interest. Elevated baseline TNF-a isassociated with MCI conversion to AD (Tarkowski et al., 2003) and
with lowerhippocampal volume (Sudheimer et al., 2014) suggesting
increased systemic TNF-amay influence hippocampal neurodegen-
eration. In a clinical population of AD patients, elevated baseline
systemic TNF-a, when combinedwith an observed systemic inflam-
matory event (SIE),was associatedwith a 10-fold greater rate of cog-
nitive decline over 6 months (Holmes et al., 2009). These studies
have lead to a small trial of the TNF-a-blockingmonoclonal antibody
etanercept in AD patients, which showed good safety and a trend
toward improved cognitive status despite being underpowered to
detect such effects (Butchart et al., 2015). However, in the current
study systemically elevated TNF-a did not induce measureable de
novo pathology. It is important to acknowledge a weakness of the
current experimental design in that the ME7 animals models used
here showed very significant synaptic and neuronal pathology prior
to TNF-a challenge. If one assumes a relatively modest de novo
injury, even if occuring selectively in the alreadydegenerating brain,
it would be predicted to be relatively difficult to detect on a back-
ground of very significant pathology, with the associated variability
between different animals. We observed inter-individual differ-
ences in severity of pathology, evident in apparently increased
Caspase-3 and IBA1 in ME7 + TNFa at 9 h, these were generally
within the range of this inter-individual variability. Nonetheless,
we have previously shown that acute exacerbation of neuropathol-
ogy is detectable after systemic LPS (at 500 lg/kg; Cunningham
et al., 2005) and we have repeated this observation here. However
blocking systemic TNF-a during LPS exposure was not sufficient to
block de novo cell death in the hippocampus of these animals. Thus,
it appears that acutely elevated TNF-a is not sufficient to induce de
novohippocampal cell death andneither is systemic TNF-a essential
for hippocampal cell death induced by LPS.
It may be significant that elevated baseline TNF-a was a stron-
ger predictor of decline than acute SIE in AD patients (Holmes
et al., 2009) and one might predict that chronic elevation of periph-
eral TNF-a levels would be a better strategy to fully address the
hypothesis that elevated systemic TNF-a is a contributor to chronic
neurodegeneration and cognitive decline (as opposed to acute cog-
nitive dysfunction occuring during acute inflammatory episodes).
Systemic TNF-a has also been shown to mediate the sickness
behavior, microglial activation and monocyte infiltration observed
during bile duct ligation (liver injury)-induced systemic inflamma-
tion (D’Mello et al., 2009). The liver injury induced by bile-duct
ligation may constitute a useful, clinically relevant, model scenario
with which to produce a more sustained systemic TNF-a response
that would alter microglial activation and indeed monocyte infil-
tration to the brain and may produce measurable impacts on the
evolution of neuropathology in the degenerating brain.5. Conclusion
The data indicate that acutely elevated TNF-a has robust acute
effects on brain function in the degenerating brain, which may be
highly relevant for illness-induced exacerbations of brain dysfunc-
tion including depression, delirium and post-operative cognitive
dysfunction but levels of this pro-inflammatory cytokine may need
to be more sustained to significantly impact on underlying
neurodegeneration.Acknowledgments
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